Company:  WARNER CHILCOTT PLC
Form Type:  10-K
Filing Date:  2/24/2012 
CIK:  0001323854 
Address:  1 GRAND CANAL SQUARE 
City, State, Zip:  DOCKLANDS, DUBLIN 2, IRELAND,  00000 
Telephone:  353 1 897 2000 
Fiscal Year:  12/31 
Description of Business
We are a leading specialty pharmaceutical company currently focused on the women�s healthcare, gastroenterology, urology and dermatology segments of the branded pharmaceuticals market, primarily in North America. We are a fully integrated company with internal resources dedicated to the development, manufacture and promotion of our products. Our franchises are comprised of complementary portfolios of established branded and development-stage products that we actively manage throughout their life cycles. Multiple products make up our existing sales base and several of these provide opportunities for future growth. Our women�s healthcare franchise is anchored by our strong presence in the hormonal contraceptive, osteoporosis and hormone therapy (�HT�) markets. Our hormonal contraceptive product offerings include: LOESTRIN 24 FE (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), the leading branded product in the U.S.
Register for EDGAR Pro and access this filing in:     
  FORM 10-K
    PART I.
      Item 1. Business.
        NAME AND TITLE
      Item 1A. Risk Factors.
      Item 1B. Unresolved Staff Comments.
      Item 2. Properties.
      Item 3. Legal Proceedings.
      Item 4. Mine Safety Disclosures.
    Part II
      Item 5. Market for Registrant's Common Equity, Related ...
      Item 6. Selected Financial Data.
      Item 7. Management's Discussion and Analysis of Financial ...
        Factors Affecting Our Results of Operations
        Financial Condition, Liquidity and Capital Resources
      Item 7A. Quantitative and Qualitative Disclosures About ...
      Item 8. Financial Statements and Supplementary Data.
      Item 9. Changes in and Disagreements with Accountants on ...
      Item 9A. Controls and Procedures.
      Item 9B. Other Information.
    Part III
      Item 10. Directors, Executive Officers and Corporate Governance.
      Item 11. Executive Compensation.
      Item 12. Security Ownership of Certain Beneficial Owners and ...
      Item 13. Certain Relationships and Related Transactions, and ...
      Item 14. Principal Accounting Fees and Services.
    PART IV.
      Item 15. Exhibits, Financial Statement Schedules.
    SIGNATURES
    Report of Independent Registered Public Accounting Firm
    BALANCE SHEET
    INCOME STATEMENT
    STOCKHOLDERS EQUITY
    CASH FLOW
    Notes to Consolidated Financial Statements
  EXHIBIT 21.1
    SUBSIDIARIES
  EXHIBIT 23.1
    CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  EXHIBIT 31.1
    CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO
  EXHIBIT 31.2
    CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO
  EXHIBIT 32.1
    CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND
BROKERAGE PARTNERS